ParagonRx® | Minimize Risk and Optimize Use

Europe's main drug regulator said it was starting a review of the Novartis AG hypertension pill aliskiren after a large clinical trial linked the drug to possible risks of nonfatal stroke and kidney problems.

While it is reviewing the benefits and risks of the drug, the European Medicines Agency, or EMA, advised doctors to stop prescribing the drug to diabetic patients who are also taking the older ...

[Link to Article]